The Oncologist: Yes, speaking of personalized treatment, we also saw an update from the phase III Southwest Oncology Group (SWOG) S1007 RxPonder trial, which evaluated the benefit of adjuvant chemotherapy based on clinical and genetic risk factors in patients with HR-positive, HER2-negative, early breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.